Table 2.
Parameter | Tigecycline (75 mg) | Tigecycline (100 mg) | Imipenem/cilastatin |
---|---|---|---|
CE population | |||
Subjects, n | 23 | 20 | 24 |
Cure, n (%) | 16 (69.6) | 17 (85.0) | 18 (75.0) |
Differenceb (70% CI) | −5.4 (−21.6, 10.9) | 10.0 (−6.1, 24.8) | N/A |
c-mITT population | |||
Subjects, n | 36 | 35 | 34 |
Cure, n (%) | 19 (52.8) | 25 (71.4) | 18 (52.9) |
Differenceb (70% CI) | −0.2 (−14.3, 14.0) | 18.5 (4.3, 31.8) | N/A |
ME population | |||
Subjects, n | 13 | 10 | 15 |
Cure, n (%) | 9 (69.2) | 8 (80.0) | 12 (80.0) |
Differenceb (70% CI) | −10.8 (−32.0, 10.9) | 0.0 (−23.8, 20.9) | N/A |
CE, clinically evaluable; CI, confidence interval; c-mITT, clinical modified intention to treat; ME, microbiologically evaluable; N/A, not applicable.
Tigecycline versus imipenem/cilastatin.